News | January 07, 2024
Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
